Herpes zoster in patients treated with biologicals

[en] Background : The incidence and severity of herpes zoster (HZ) appear increased in patients receiving tumor necrosis factor-alpha antagonists. Objective : To study the incidence and clinical features of HZ in 1,220 patients (4.206 patient-years) receiving either adalimumab, etanercept, infliximumab, rituximab or ustekinumab. Results: Twenty-two HZ cases were identified (1.26% of total cohort; adalimumab: 11/1,546 patient-years, incidence rate (IR) 7.1; etanercept: 4/789 patient-years, IR5.1; rituximab: 1/168 patient-years, IR 5.2; ustekinumab: 2/37 patient-years, IR53.5; infliximab: 4/1.666 patient-years, IR 2.4). The time to event varied widely (1.5-108 months). Extensive HZ was reported in 45 and 32% of the cases, respectively. Persistent postzoster neuralgia (PHN;>6months) was observed in 5/20 patients. Conclusions: The Hz incidence was 2.1-fold higher among patients over 60 years, compared with a reference population, although not statistically significant. Severe, multidermatomal HZ and persistent PHN were common.

Disciplines :

Dermatology

Author, co-author :

FAILLA, Valérie ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

JACQUES, Jessica ; Centre Hospitalier Universitaire de Liège - CHU > Service d'Informations médico économiques (SIME)

CASTRONOVO, Charlotte ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

NIKKELS, Arjen ; Centre Hospitalier Universitaire de Liège - CHU > Dermatologie

Language :

English

Title :

Herpes zoster in patients treated with biologicals

Publication date :

2012

Journal title :

Dermatology

ISSN :

1018-8665

eISSN :

1421-9832

Publisher :

Karger, Basel, Switzerland

Available on ORBi :

since 30 May 2012

Statistics

Number of views

89 (13 by ULiège)

Number of downloads

4 (2 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al: Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-1371.
Saketkoo LA, Espinoza LR: Impact of biologic agents on infectious diseases. Infect Dis Clin North Am 2006; 20: 931-961.
Shale MJ: The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull 2009; 92: 61-77.
Domm S, Cinatl J, Mrowietz U: The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
Wendling D, Streit G, Toussirot E, Prati C: Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. Joint Bone Spine 2008; 75: 540-543.
Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ: Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol 2009; 104: 2524-2533.
Haroon N, Inman RD: Infectious complications of biological therapy. Curr Opin Rheumatol 2009; 21: 397-403.
Baumgart DC, Dignass AU: Shingles following infliximab infusion. Ann Rheum Dis 2002; 61: 661.
Bongartz T, Orenstein R: The risk of herpes zoster: another cost of anti-TNF therapy? Nat Rev Rheumatol 2009; 5: 361-363.
Kim SY, Solomon DH: Tumor necrosis factor blockade and the risk of viral infection. Nat Rev Rheumatol 2010; 6: 165-174.
Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S: The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. Int J Rheum Dis 2009; 12: 118-124.
Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al: Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744.
Ito K, Okamoto M, Maruyama F, Handa K, Yamamoto Y, Watanabe M, et al: Alteration in antibody-mediated immunity in patients with rituximab-combined chemotherapy and incidence of herpes zoster. Gan To Kagaku Ryoho 2010; 37: 99-102.
Mishra R, Singh V, Pritchard CH: Safety of biologic agents after rituximab therapy in patients with rheumatoid arthritis. Rheumatol Int 2009; 31: 481-484.
Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, et al: Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70: 616-623.
Kinder A, Stephens S, Mortimer N, Sheldon P: Severe herpes zoster after infliximab infusion. Postgrad Med J 2004; 80: 26.
Manzano V, Ruiz P, Torres M, Gomez F: Severe pneumonia by aciclovir-resistant varicella-zoster virus during etanercept therapy. Rheumatology 2010; 49: 1791-1793.
Nobile S, Catassi C, Felici L: Herpes zoster infection followed by Henoch-Schönlein purpura in a girl receiving infliximab for ulcerative colitis. J Clin Rheumatol 2009; 15: 101.
Tresch S, Trueb RM, Kamarachev J, French LE, Hofbauer GF: Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. Dermatology 2009; 219: 347-349.
Kunz AN, Rajnik M: Disseminated cutaneous varicella zoster virus infections during infliximab therapy for Crohn's disease: case report of two pediatric patients at one institution. Clin Pediatr 2011; 50: 559-561.
Failla V, Nikkels AF: Ustekinumab and herpes zoster. Dermatology 2011; 222: 119-122.
Failla V, Castronovo C, Meex C, Nikkels AF: Protracted herpes zoster and severe postherpetic neuralgia after inadvertant infliximab administration. Eur J Dermatol 2011; 21: 782-783.
Buccoliero G, Lonero G, Romanelli C, Loperfido P, Resta F: Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. New Microbiol 2010; 33: 271-274.
Whitley RJ, Gnann JW: Herpes zoster in the age of focused immunosuppressive therapy. JAMA 2009; 301: 774-775.
Hope-Simpson RE: The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965; 58: 9-20.
Serac G, Tubach F, Mariette X, Salmon-Céron D, Ravaud P, Lioté F, et al: Risk of herpes zoster in patients receiving anti-TNF- in the prospective French RATIO registry. J Invest Dermatol 2012; 132: 726-729.
García-Doval I, Pérez-Zafrilla B, Descalzo MA, Roselló R, Hernandez MV, Gómez-Reino JJ, et al: Incidence and risk of hospitalization due to shingles and chickenpox in patients with rheumatic diseases treated with TNF antagonists. Ann Rheum Dis 2010; 69: 1751-1755.
Dreiher J, Kresch FS, Comanesther D, Cohen AD: Risk of herpes zoster in patients with psoriasis treated with biologics. J Eur Acad Dermatol Venereol DOI: 10.1111/j.1468-3083.2011.04230.x.
Antonelli MA, Moreland LW, Brick JE: Herpes zoster in patients with rheumatoid arthritis treated with weekly, low-dose methotrexate. Am J Med 1991; 90: 295-298.
Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30: 2563-2571.
Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human antitumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411.
Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004; 50: 1051-1065.
Lipsky PE, van der Heijde DM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al: Anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study group. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-1602.
Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al: Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. J Rheumatol 2006; 33: 854-861.
Sanders HWA: Herpes zoster in de huisartspraktijk; PhD thesis, Drukkerij Helmond, Helmond, 1968, pp 1-179.
Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD: Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48:S2-7.
Jung BF, Johnson RW, Griffin DR, Dworkin RH: Risk factors for postherpetic neuralgia in patients with herpes zoster. Neurology 2004; 62: 1545-1551.
Opstelten W, Zuithoff NP, van Essen GA, van Loon AM, van Wijck AJ, Kalkman CJ, et al: Predicting postherpetic neuralgia in elderly primary care patients with herpes zoster: prospective prognostic study. Pain 2007; 132(suppl 1):S52-59.
Javed S, Kamili QU, Mendoza N, Tyring SK: Possible association of lower rate of postherpetic neuralgia in patients on anti-tumor necrosis factor. J Med Virol 2011; 83: 2051-2055.
Nikkels AF, Piérard GE: Oral antivirals revisited in the treatment of herpes zoster. What do they accomplish? Am J Clin Dermatol 2002; 3: 591-598.